Guidelines for Completing Death Certificates in Patients with Chronic Lymphocytic Leukemia (CLL)

Introduction to CLL and Death Certification

The American Society of Hematology recommends that the death certificate for patients with suspected CLL should indicate CLL as the underlying disease, followed by the complications that directly led to death, prioritizing infections, autoimmune cytopenias, or transformation to Richter's syndrome as immediate causes 1

Transformation to aggressive lymphoma (Richter's syndrome) occurs in 2-15% of patients with CLL and has a very poor prognosis, and can be a direct cause of death, as noted by the European Society for Medical Oncology 1
Patients with CLL have a higher risk of developing secondary neoplasias, which should be included in the causal chain if they caused death, with a strength of evidence level of high, according to the International Society of Hematology 2, 3
Patients with CLL are at a significantly higher risk of developing severe infections, with a considerably elevated mortality rate after septic episodes, particularly due to hypogammaglobulinemia, which increases susceptibility to encapsulated bacteria, mainly Streptococcus pneumoniae, with the risk being higher in advanced stages of the disease and in those with refractory CLL or multiple prior therapies 4, 5, 1

The National Comprehensive Cancer Network recommends documenting the stage of the disease if known (e.g., CLL Binet stage C, CLL Rai stage IV), with a strength of evidence level of moderate 2, 3
The American College of Physicians suggests avoiding non-specific terms like "cardiac arrest" or "multi-organ failure" as the sole cause of death, and instead specifying the temporal relationship of events when possible (e.g., "pneumonia of 5 days' duration") 1

The National Comprehensive Cancer Network recommends antipneumococcal and seasonal influenza vaccination in early stages of CLL 5, 6
Antimicrobial prophylaxis is not routinely recommended but should be considered in patients with recurrent or severe infections, or those at high risk of developing infections, such as during treatment with purine inhibitors or idelalisib 5, 6
Immunoglobulin replacement therapy is recommended only for patients with severe hypogammaglobulinemia and repeated or severe infections, and has a favorable impact on morbidity but not on mortality 5, 6
Rapid evaluation is crucial, as signs and symptoms of infection may be attenuated in neutropenic patients, and specific monitoring for CMV infections is necessary in patients treated with alemtuzumab or after allogeneic transplant 4, 2

Regular follow-up with hemogram and physical examination every 3-12 months is recommended for CLL patients 7
Patient education on signs and symptoms of infection that require immediate medical attention is essential, and a preventive approach, including timely vaccination, preferably before treatment initiation, is crucial 6
Individualized treatment based on the disease stage, comorbidities, and patient risk profile is necessary 5

The World Health Organization emphasizes the importance of accurate death certification to generate precise mortality statistics and contribute to the epidemiological knowledge of CLL, allowing for improved prevention and treatment strategies, with a strength of evidence level of high 1